Current Liabilities decreased faster than Biodesix Inc 's Cash & cash equivalent, this led to improvement in Biodesix Inc 's Quick Ratio to 1.99, above Biodesix Inc average Quick Ratio.

Within Medical Laboratories industry 17 other companies have achieved higher Quick Ratio than Biodesix Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1152 to 1430.

Explain Quick Ratio?
How much Cash & cash equivalents BDSX�s has?
What are BDSX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BDSX/financial-strength

https://api.csimarket.com/api/v1/companies/BDSX/fundamentals

https://api.csimarket.com/api/v1/companies/BDSX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

BDSX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-21.51 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	71.1 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.99	Subscribe	Subscribe	Subscribe	Subscribe
BDSX's Total Ranking	# 1430	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-6.82 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-5.29 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 18
Healthcare Sector	# 507
Overall Market	# 1430

Quick Ratio Statistics
High	Average	Low
4.03	1.4	0.14
(Mar 31 2021)		(Sep 30 2020)

Financial Statements
Biodesix Inc 's Current Liabilities	$ 14 Millions	Visit BDSX's Balance sheet
Biodesix Inc 's Cash & cash equivalent	$ 28 Millions	Visit BDSX's Balance sheet
Source of BDSX's Sales		Visit BDSX's Sales by Geography

Cumulative Biodesix Inc 's Quick Ratio

BDSX's Quick Ratio for the trailling 12 Months

BDSX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	0.85 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	26.83 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.68	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1094	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-5.97 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	12.95 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to BDSX Financial Strength Comparisons >> Go to Compare BDSX Quick Ratio to its Competitors

On the trailing twelve months basis BDSX Cash & cash equivalent soared by 71.1 % in Q3 2026 year on year, while Current Liabilities decreased to $14 millions, this led to increase in in Biodesix Inc 's Quick Ratio to 1.68, above BDSX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 33 other companies have achieved higher Quick Ratio than Biodesix Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2853 to 3893.

Explain Quick Ratio?
How much Cash & cash equivalents BDSX�s has?
What are BDSX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 34
Healthcare Sector	# 886
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.4	1.19	0.05
(Sep 30 2021)		(Sep 30 2020)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Laboratories Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Personalis Inc	5.17	$ 254.841 Millions	$ 49.274 Millions
Veracyte Inc	4.40	$ 370.532 Millions	$ 84.209 Millions
Castle Biosciences Inc	4.11	$ 277.665 Millions	$ 67.612 Millions
Fulgent Genetics Inc	4.07	$ 292.739 Millions	$ 71.877 Millions
Omniab Inc	3.81	$ 64.210 Millions	$ 16.853 Millions
Guardant Health Inc	2.75	$ 1,026.848 Millions	$ 373.165 Millions
Incyte Corporation	2.68	$ 3,854.572 Millions	$ 1,437.818 Millions
Exagen Inc	2.14	$ 28.092 Millions	$ 13.100 Millions
Biodesix Inc	1.99	$ 28.409 Millions	$ 14.248 Millions
Caredx Inc	1.80	$ 250.480 Millions	$ 138.975 Millions
Butterfly Network Inc	1.80	$ 122.301 Millions	$ 67.987 Millions
Sera Prognostics Inc	1.80	$ 44.089 Millions	$ 24.527 Millions
Radnet Inc	1.11	$ 797.880 Millions	$ 716.642 Millions
Bioaffinity Technologies Inc	1.01	$ 2.550 Millions	$ 2.533 Millions
Lumexa Imaging Holdings Inc	0.49	$ 90.011 Millions	$ 183.456 Millions
Quest Diagnostics Inc	0.49	$ 893.000 Millions	$ 1,834.000 Millions
Medpace Holdings Inc	0.47	$ 705.315 Millions	$ 1,496.097 Millions

Date modified: 2026-11-08T19:11:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.